Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib versus investigator's choice in relapsed or refractory chronic lymphocytic leukemia
2015-004454-17Phase 3Completed
- Sponsor
- Acerta Pharma
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acalabrutinib, idelalisib, rituximab and bendamustine in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Acerta Pharma. Primary endpoint: Progression-free survival. Started Aug 2016; status: completed.
02
Drugs
acalabrutinibidelalisibrituximabbendamustine
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2015-004454-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004454-17.